These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12490073)

  • 1. Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis.
    Suzuki H; Willingham MC; Cheng SY
    Thyroid; 2002 Nov; 12(11):963-9. PubMed ID: 12490073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer.
    Kim CS; Ying H; Willingham MC; Cheng SY
    Carcinogenesis; 2007 May; 28(5):932-9. PubMed ID: 17127711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tumor suppressor role for thyroid hormone beta receptor in a mouse model of thyroid carcinogenesis.
    Kato Y; Ying H; Willingham MC; Cheng SY
    Endocrinology; 2004 Oct; 145(10):4430-8. PubMed ID: 15231697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma.
    Ying H; Suzuki H; Furumoto H; Walker R; Meltzer P; Willingham MC; Cheng SY
    Carcinogenesis; 2003 Sep; 24(9):1467-79. PubMed ID: 12869418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor gamma during thyroid carcinogenesis.
    Ying H; Suzuki H; Zhao L; Willingham MC; Meltzer P; Cheng SY
    Cancer Res; 2003 Sep; 63(17):5274-80. PubMed ID: 14500358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked potentiation of the dominant negative action of a mutant thyroid hormone receptor beta in mice by the ablation of one wild-type beta allele.
    Suzuki H; Zhang XY; Forrest D; Willingham MC; Cheng SY
    Mol Endocrinol; 2003 May; 17(5):895-907. PubMed ID: 12576488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosomal aberrations in cell lines derived from thyroid tumors spontaneously developed in TRbetaPV/PV mice.
    Zimonjic DB; Kato Y; Ying H; Popescu NC; Cheng SY
    Cancer Genet Cytogenet; 2005 Sep; 161(2):104-9. PubMed ID: 16102579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer.
    Ying H; Willingham MC; Cheng SY
    Oncogene; 2008 Jan; 27(6):823-30. PubMed ID: 17653082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma.
    Kim CS; Vasko VV; Kato Y; Kruhlak M; Saji M; Cheng SY; Ringel MD
    Endocrinology; 2005 Oct; 146(10):4456-63. PubMed ID: 16002527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gelsolin: a novel thyroid hormone receptor-beta interacting protein that modulates tumor progression in a mouse model of follicular thyroid cancer.
    Kim CS; Furuya F; Ying H; Kato Y; Hanover JA; Cheng SY
    Endocrinology; 2007 Mar; 148(3):1306-12. PubMed ID: 17170101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.
    Guigon CJ; Zhao L; Willingham MC; Cheng SY
    Oncogene; 2009 Jan; 28(4):509-17. PubMed ID: 18997818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma.
    Lu C; Zhao L; Ying H; Willingham MC; Cheng SY
    Endocrinology; 2010 Apr; 151(4):1929-39. PubMed ID: 20133453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma.
    Zhu XG; Zhao L; Willingham MC; Cheng SY
    Oncogene; 2010 Apr; 29(13):1909-19. PubMed ID: 20062085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.
    Zhu X; Zhao L; Park JW; Willingham MC; Cheng SY
    Neoplasia; 2014 Sep; 16(9):757-69. PubMed ID: 25246276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-tissue gene-expression analysis in a mouse model of thyroid hormone resistance.
    Miller LD; McPhie P; Suzuki H; Kato Y; Liu ET; Cheng SY
    Genome Biol; 2004; 5(5):R31. PubMed ID: 15128445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of thyroid hormone receptor isoforms dictates the dominant negative activity of mutant Beta receptor.
    Zhang XY; Kaneshige M; Kamiya Y; Kaneshige K; McPhie P; Cheng SY
    Mol Endocrinol; 2002 Sep; 16(9):2077-92. PubMed ID: 12198244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway.
    Kato Y; Ying H; Zhao L; Furuya F; Araki O; Willingham MC; Cheng SY
    Oncogene; 2006 May; 25(19):2736-47. PubMed ID: 16314832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor.
    Guigon CJ; Zhao L; Lu C; Willingham MC; Cheng SY
    Mol Cell Biol; 2008 Jul; 28(14):4598-608. PubMed ID: 18474620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis.
    Guigon CJ; Cheng SY
    Mol Cell Endocrinol; 2009 Sep; 308(1-2):63-9. PubMed ID: 19549593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.
    Furuya F; Hanover JA; Cheng SY
    Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1780-5. PubMed ID: 16446424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.